BBA
DAWN

Baker Bros. Advisors’s Day One Biopharmaceuticals DAWN Stock Holding History

Baker Bros. Advisors’s Portfolio DAWN Stock Details DAWN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1,000,000
Closed -$14.6M – 88
2023
Q4 		$14.6M Hold
1,000,000
– – 0.17% 41
2023
Q3 		$12.3M Hold
1,000,000
– – 0.07% 42
2023
Q2 		$11.9M Buy
+1,000,000
New +$13.1M 0.07% 51

Other funds holding DAWN

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Baker Bros. Advisors's DAWN Position: Q1 2024 in Review

Baker Bros. Advisors sold out of Day One Biopharmaceuticals (DAWN) in Q1 2024, closing a stake of 1,000,000 shares — an estimated $14.6M sold.

Baker Bros. Advisors first reported a position in DAWN in Q2 2023 and held it in 3 quarters. The position peaked at $14.6M in Q4 2023. 149 funds tracked by Wall St. Rank hold DAWN as of Q1 2024.

  • Baker Bros. Advisors reported no remaining Day One Biopharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Baker Bros. Advisors sold 1,000,000 Day One Biopharmaceuticals shares in Q1 2024, an estimated $14.6M.
  • Baker Bros. Advisors first reported a position in Day One Biopharmaceuticals in Q2 2023 and held it in 3 quarters.
  • Baker Bros. Advisors's Day One Biopharmaceuticals position peaked at $14.6M in Q4 2023.
  • 149 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q1 2024.

Based on Baker Bros. Advisors's 13F filing for Q1 2024, filed 15 May 2024.